Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment
BACKGROUND: Mutations of the proto-oncogene BRAF have been described in many cancers. Mutated BRAF causes overactive downstream signaling via MEK and ERK leading to excessive cell proliferation and survival. Their identification is of real interest because specific inhibitors have been developed. ME...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872282/ https://www.ncbi.nlm.nih.gov/pubmed/24386625 http://dx.doi.org/10.1186/2193-1801-2-679 |
_version_ | 1782296937648619520 |
---|---|
author | Boyrie, Sabrina Fauquet, Isabelle Rives, Michel Genebes, Caroline Delord, Jean-Pierre |
author_facet | Boyrie, Sabrina Fauquet, Isabelle Rives, Michel Genebes, Caroline Delord, Jean-Pierre |
author_sort | Boyrie, Sabrina |
collection | PubMed |
description | BACKGROUND: Mutations of the proto-oncogene BRAF have been described in many cancers. Mutated BRAF causes overactive downstream signaling via MEK and ERK leading to excessive cell proliferation and survival. Their identification is of real interest because specific inhibitors have been developed. METHODS AND RESULTS: We report the case of a patient with an aggressive cystadenocarcinoma of the parotid with synchronous metastases. Cisplatine/5FU chemotherapy associated with palliative radiation therapy was used first without any efficency nor clinical improvement. A molecular analysis revealed a BRAF mutation. A compassionate treatment with a BRAF inhibitor showed very good results from the first month. The patient reported real improvement in clinical condition and pain. From an imaging point of view, computed tomographies reported a complete response on mediastinal lymph nodes and regeneration on bone metastases. CONCLUSION: This first report suggests BRAF could be a potent oncogenic driver in salivary gland carcinoma. It deserves a multicenter academic prospective trial to provide proof of efficiency with BRAF inhibitors in theses tumors. |
format | Online Article Text |
id | pubmed-3872282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-38722822014-01-02 Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment Boyrie, Sabrina Fauquet, Isabelle Rives, Michel Genebes, Caroline Delord, Jean-Pierre Springerplus Case Study BACKGROUND: Mutations of the proto-oncogene BRAF have been described in many cancers. Mutated BRAF causes overactive downstream signaling via MEK and ERK leading to excessive cell proliferation and survival. Their identification is of real interest because specific inhibitors have been developed. METHODS AND RESULTS: We report the case of a patient with an aggressive cystadenocarcinoma of the parotid with synchronous metastases. Cisplatine/5FU chemotherapy associated with palliative radiation therapy was used first without any efficency nor clinical improvement. A molecular analysis revealed a BRAF mutation. A compassionate treatment with a BRAF inhibitor showed very good results from the first month. The patient reported real improvement in clinical condition and pain. From an imaging point of view, computed tomographies reported a complete response on mediastinal lymph nodes and regeneration on bone metastases. CONCLUSION: This first report suggests BRAF could be a potent oncogenic driver in salivary gland carcinoma. It deserves a multicenter academic prospective trial to provide proof of efficiency with BRAF inhibitors in theses tumors. Springer International Publishing 2013-12-18 /pmc/articles/PMC3872282/ /pubmed/24386625 http://dx.doi.org/10.1186/2193-1801-2-679 Text en © Boyrie et al.; licensee Springer. 2013 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Study Boyrie, Sabrina Fauquet, Isabelle Rives, Michel Genebes, Caroline Delord, Jean-Pierre Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment |
title | Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment |
title_full | Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment |
title_fullStr | Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment |
title_full_unstemmed | Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment |
title_short | Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment |
title_sort | cystadenocarcinoma of the parotid: case report of a braf inhibitor treatment |
topic | Case Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872282/ https://www.ncbi.nlm.nih.gov/pubmed/24386625 http://dx.doi.org/10.1186/2193-1801-2-679 |
work_keys_str_mv | AT boyriesabrina cystadenocarcinomaoftheparotidcasereportofabrafinhibitortreatment AT fauquetisabelle cystadenocarcinomaoftheparotidcasereportofabrafinhibitortreatment AT rivesmichel cystadenocarcinomaoftheparotidcasereportofabrafinhibitortreatment AT genebescaroline cystadenocarcinomaoftheparotidcasereportofabrafinhibitortreatment AT delordjeanpierre cystadenocarcinomaoftheparotidcasereportofabrafinhibitortreatment |